The combination of pembrolizumab (a programmed cell death-1 inhibitor) and axitinib (a tyrosine kinase inhibitor) resulted in better outcomes than sunitinib among the patients with previously untreated advanced RCC (59). The gene discussed is PDCD1; the disease is renal cell carcinoma.